A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Looking into the current session, Regeneron Pharmaceuticals Inc. ( NASDAQ:REGN ) shares are trading at $603.61, after a 0.60% increase. Moreover, over the past month, the stock increased by 5.27%, but in the past year, fell by 39.40%.
Nvidia, Amphenol, Lockheed Martin And A Health Care Stock On CNBC's 'Final Trades' - Lockheed Martin ( NYSE:LMT ) , Amphenol ( NYSE:APH )
On CNBC's "Halftime Report Final Trades," Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, said he is sticking with NVIDIA Corporation ( NASDAQ:NVDA ) and not selling the stock.
Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday - Acuity ( NYSE:AYI ) , AES ( NYSE:AES )
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday. Shares of Acuity Inc. ( NYSE:AYI ) rose sharply during Wednesday's session following better-than-expected fourth-quarter earnings. It clocked an adjusted EPS of $5.20, beating the analyst consensus ...
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
TARRYTOWN, N.Y., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial markets open.
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 - Regeneron Pharmaceuticals ( NASDAQ:REGN )
TARRYTOWN, N.Y., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial markets open.
2 Beaten-Down Stocks to Buy and Hold for a Decade
These biotechs should benefit from their innovative ways.
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder - Regeneron Pharmaceuticals ( NASDAQ:REGN )
The U.S. Food and Drug Administration ( FDA ) on Friday approved Regeneron Pharmaceuticals, Inc.'s ( NASDAQ: REGN ) Evkeeza ( evinacumab-dgnb ) ANGPTL3 antibody as an adjunct to diet and exercise and other lipid-lowering therapies for the treatment of children from age 1 to less than 5 years old ...
Evkeeza® ( evinacumab-dgnb ) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol - Regeneron Pharmaceuticals ( NASDAQ:REGN )
TARRYTOWN, N.Y., Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that the U.S.
Evkeeza® ( evinacumab-dgnb ) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia ...
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch - Eli Lilly ( NYSE:LLY )
On Wednesday, Eli Lilly & Co. ( NYSE: LLY ) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. The company cited strategic business reasons for halting the trial, though a parallel study in non-diabetic obesity ...
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran ( nex-z ) in Patients with Hereditary Transthyretin ( ATTR ) Amyloidosis with Polyneuropathy - Intellia Therapeutics ( NASDAQ:NTLA )
One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three years Stabilization or improvement in disease-related clinical measures observed at 24 months
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran ( nex-z ) in Patients with Hereditary Transthyretin ( ATTR ) Amyloidosis with Polyneuropathy
CAMBRIDGE, Mass., Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced longer-term follow-up data from the ongoing Phase 1 study of ...
What Does the Market Think About Regeneron Pharmaceuticals? - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Pharmaceuticals's REGN short interest as a percent of float has risen 20.52% since its last report. According to exchange reported data, there are now 2.83 million shares sold short, which is 2.76% of all regular shares that are available for trading.
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection - Scholar Rock Holding ( NASDAQ:SRRK )
The U.S. Food and Drug Administration ( FDA ) on Tuesday issued a Complete Response Letter ( CRL ) for Scholar Rock's SRRK apitegromab Biologics License Application ( BLA ) for spinal muscular atrophy ( SMA ) .
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran ( nex-z ) for the Treatment of Hereditary Transthyretin ( ATTR ) Amyloidosis with Polyneuropathy
Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 highlighting up to three years of patient follow-up and additional insight into ATTRv-PN disease-relevant measures Longer-term data to be presented at the 5th International ...
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran ( nex-z ) for the Treatment of Hereditary Transthyretin ( ATTR ) Amyloidosis with Polyneuropathy - Intellia Therapeutics ( NASDAQ:NTLA )
CAMBRIDGE, Mass., Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc.
Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion ...
Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo
Dupixent® ( dupilumab ) to Treat Chronic Spontaneous Urticaria ( CSU ) Advances in EU with Positive CHMP Opinion - Regeneron Pharmaceuticals ( NASDAQ:REGN )
TARRYTOWN, N.Y. and PARIS, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.
Dupixent® ( dupilumab ) to Treat Chronic Spontaneous Urticaria ( CSU ) Advances in EU with Positive CHMP Opinion
Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo ...
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
Here's what needs to happen for these high flyers to continue soaring.
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
Inmazeb® ( atoltivimab, maftivimab, and odesivimab-ebgn ) was the first treatment approved by the U.S. Food and Drug Administration ( FDA ) for Orthoebolavirus zairense, also known as Zaire ...
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Inmazeb® ( atoltivimab, maftivimab, and odesivimab-ebgn ) was the first treatment approved by the U.S. Food and Drug Administration ( FDA ) for Orthoebolavirus zairense, also known as Zaire ebolavirus TARRYTOWN, N.Y., Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.
Regeneron Touts Positive Data From Phase 3 Study - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Garetosmab reduced new bone lesions by 94% ( 3 mg/kg ) and 90% ( 10 mg/kg ) vs placebo at 56 weeks. No deaths reported; treatment was well tolerated with no serious bleeding events. Up Next: Wall Street trader's 34-0 strategy goes public this week. See it first →
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
Complete 26-week results further demonstrate that combining semaglutide with trevogrumab ( anti-GDF8/anti-myostatin ) helped prevent about half of semaglutide-induced loss of lean mass, while increasing fat mass loss ...
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Regeneron Pharmaceuticals ( NASDAQ:REGN )
NEW YORK, Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc.
Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Libtayo plus chemo extended median survival to 21.1 months vs 12.9 months for chemo alone. Five-year survival was 19.4% with Libtayo combo compared to 8.8% with chemo. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On Regeneron Pharmaceuticals, Inc.
Libtayo® ( cemiplimab ) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer - Regeneron Pharmaceuticals ( NASDAQ:REGN )
TARRYTOWN, N.Y., Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.
Libtayo® ( cemiplimab ) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone ...
What's Happening With Regeneron Pharma Stock On Monday? - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Cat allergy trial cuts ocular itch by 52%, redness by 39% and skin reactions by 44% with no serious side effects. Birch allergy trial reduces itch by 51%, redness by 46% and skin reactions by 44%, with a strong safety profile. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo ...
2 Beaten-Down Stocks to Buy on the Dip
The market may be overlooking these companies' long-term potential.
Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
TARRYTOWN, N.Y., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Monday, September 8, 2025.
Why Is Sanofi Stock Tumbling Thursday? - Sanofi ( NASDAQ:SNY )
Sanofi's amlitelimab met trial endpoints but lagged Dupixent and rivals in strength. Shares fell as investors doubted its potential as a true Dupixent successor. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day
Cisco, ServiceNow, Truist Financial On CNBC's 'Final Trades' - Cisco Systems ( NASDAQ:CSCO ) , ServiceNow ( NYSE:NOW )
Jason Snipe of Odyssey Capital Advisors likes ServiceNow. Amy Raskin says Regeneron's stock has been cut into half on Eylea concerns. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day On CNBC's "Halftime Report Final Trades," Jim Lebenthal, partner at Cerity Partners, said ...
MongoDB To Rally Around 63%? Here Are 10 Top Analyst Forecasts For Wednesday - American Airlines Group ( NASDAQ:AAL ) , Heico ( NYSE:HEI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs raised American Airlines Group Inc. AAL price target from $8 to $10.
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Cemdisiran monotherapy achieved 74% complement inhibition, showing numerically better results than combo therapy. No meningococcal infections or discontinuations due to adverse events were reported through week 24. See the 6X seasonal strategy set to target this fall's biggest opportunities.
Immuneering Stock Rises 21.7% on Supply Agreement With LLY
IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living ( MG-ADL ) total score ...
What's Going On With Novo Nordisk Stock Monday? - Novo Nordisk ( NYSE:NVO )
At least 20 deviations linked to hair contamination have been reported since July 2024. Investigations often lacked root cause analysis and CAPA effectiveness checks. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here → The U.S.
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts
These companies aren't performing as badly as their stock-market performances this year suggest.
FDA Extends Review Period of REGN's Submission for Eylea HD
The FDA extends action dates for Regeneron's Eylea HD filings following inspection findings at Catalent Indiana. Nonetheless, Eylea HD remains available through vial administration.
EYLEA HD® ( aflibercept ) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
TARRYTOWN, N.Y., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that the U.S. Food and Drug Administration ( FDA ) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® ( aflibercept ) Injection 8 mg regulatory ...
Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- North America leads market expansion as companies advance next-generation ophthalmic therapies to address rising prevalence of vision-threatening diseases The global ophthalmology drugs market, valued at US$18.34 billion in 2024, stood at ...
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm
VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.
Brandon Hall Group™ Announces 2025 HCM Excellence Awards® Winners in Live Broadcast
Boca Raton, FL, Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Brandon Hall Group™, the leading HCM research and analyst firm, today announced the winners of its 2025 HCM Excellence Awards® during a special live broadcast.
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and ...
